Compiled by Rupeestop LLP, SEBI RIA INA000022701. NAV as on 18 Aug 2026. Factsheet Jun 2026. About · Disclosures
Nippon India Nifty Pharma ETF - Growth Plan
Nippon India Mutual FundEtfsDirectGrowthVery high risk
NAV
₹27.1122
As on 18 Aug 2026
Vs category
| Period | This fund | Category | Rank |
|---|---|---|---|
| 1 year | +19.49% | — | — |
| 3 year | +20.35% | — | — |
| 5 year | +14.55% | — | — |
Returns
From NAVs through 18 Aug 2026
1Y
+19.49%
Total
3Y
+20.35%
p.a.
5Y
+14.55%
p.a.
SI
+13.15%
p.a.
Calendar years
-10.86%2022
+34.44%2023
+39.59%2024
-2.46%2025
+16.49%2026 YTD
Rolling 1-year · 49 overlapping windows
-14.29%avg +16.00%+61.01%
Fund facts
Fund details from the Jun 2026 factsheet
Fund size
₹1,622.31 Cr
Expense ratio
0.18%
Exit load
None
Lock-in
None
BenchmarkNIFTY Pharma TRI
Launched05 Jul 2021
Risk levelVery high
StructureOpen Ended
ISININF204KC1089
Where the money is invested
Split by asset type.
By asset type
Equity99.96%
Cash0.04%
What the fund holds
23 holdings · portfolio as on 30 May 2026
- 21.42%Sun Pharmaceuticals Industries LtdHealthcare
- 9.53%Divi's Laboratories LtdHealthcare
- 8.93%Dr Reddy's Laboratories LtdHealthcare
- 8.86%Cipla LtdHealthcare
- 6.18%Lupin LtdHealthcare
- 5.96%Laurus Labs LtdHealthcare
- 5.19%Torrent Pharmaceuticals LtdHealthcare
- 4.48%Aurobindo Pharma LtdHealthcare
- 3.85%Glenmark Pharmaceuticals LtdHealthcare
- 3.62%Alkem Laboratories LtdHealthcare
Concentration
Top 5 weight
54.93%
Top 10 weight
78.03%
Avg turnover
20.93%
Risk and quality measures
How steady the returns have been.
Return quality
Sharpe
0.97
Below category avg 0.98
Sortino
1.39
Return per unit of downside risk
Alpha
-0.01
Return above the benchmark
Risk
Std deviation
16.47%
How much returns swing
Beta
0.95
Below category avg 0.95
R-squared
92.2%
How closely it tracks the benchmark
Who manages this fund
1 fund manager
- JTJitendra Tolani1.1 years in the industryRuns 11 schemes
Other Etfs funds
Axis Equity Etfs FOF Direct GrowthdirectCompare
Motilal Oswal Gold and Silver Etfs Fund of Funds Direct GrowthdirectCompare- Motilal Oswal Developed Market Ex US Etfs Fund of Funds - Direct Plan - GrowthdirectCompare
Mirae Asset Global Electric & Autonomous Vehicles Etfs Fund of Fund Direct Plan - GrowthdirectCompare
Aditya Birla Sun Life US Treasury 1-3 Year Bond Etfs Fund of Funds-Direct Plan-GrowthdirectCompare- Aditya Birla Sun Life US Treasury 3-10 Year Bond Etfs Fund of Funds-Direct Plan-GrowthdirectCompare
- Axis Equity Etfs FOF Direct IDCW PayoutdirectCompare
- Axis Equity Etfs FOF Direct IDCW ReinvestmentdirectCompare
SIP illustration
Rate
+20.35%
Invested
₹6,00,000
Illustrated
₹19,55,615
₹5,000/mo × 10 years at this fund's 3Y CAGR. Illustration, not a forecast. SIP calculator
FAQ
What is Nippon India Nifty Pharma ETF - Growth Plan NAV today?
- The latest NAV of Nippon India Nifty Pharma ETF - Growth Plan is ₹27.1122 as on 18 Aug 2026.
How has Nippon India Nifty Pharma ETF - Growth Plan performed vs its category?
- 1-year return +19.49%. Past performance does not guarantee future returns.
What are the returns of Nippon India Nifty Pharma ETF - Growth Plan?
- Trailing returns from published NAVs: 1 year +19.49%, 3 year +20.35% a year, 5 year +14.55% a year, since our first NAV +13.15% a year. Past performance does not guarantee future returns.
How would a SIP in Nippon India Nifty Pharma ETF - Growth Plan have been illustrated?
- The SIP illustration on this page uses ₹5,000 a month for 10 years at this fund's 3-year annualised return of +20.35%. It is not a forecast.
What is the expense ratio and fund size of Nippon India Nifty Pharma ETF - Growth Plan?
- For Nippon India Nifty Pharma ETF - Growth Plan, the expense ratio is 0.18% and fund size (AUM) is ₹1,622.31 Cr.
What is the ISIN of Nippon India Nifty Pharma ETF - Growth Plan?
- The ISIN for Nippon India Nifty Pharma ETF - Growth Plan is INF204KC1089.
Mutual fund investments are subject to market risks. Read all scheme related documents carefully before investing. Past performance does not guarantee future returns and is not an indicator of future results.
Figures on this page come from published NAVs and the scheme's monthly factsheet. They are for information only and are not investment advice or a recommendation to buy or sell any scheme.